Published in final edited form as:

ACS Nano. 2017 December 26; 11(12): 11954–11968. doi:10.1021/acsnano.7b00186.

Harnessing Sphingosine-1-Phosphate Signaling and Nanotopographical Cues to Regulate Skeletal Muscle Maturation and Vascularization

Jonathan H. Tsui^{#1}, Kajohnkiart Janebodin^{#1,2,3}, Nicholas Ieronimakos^{1,2,4}, David M. P. Yama¹, Hee Seok Yang^{1,5}, Rakchanok Chavanachat¹, Aislinn L. Hays^{2,7}, Haeshin Lee⁶, Morayma Reyes^{2,7,#}, and Deok-Ho Kim^{1,8,9,#}

¹Department of Bioengineering, University of Washington, Seattle, Washington, USA

²Department of Pathology, University of Washington, Seattle, Washington, USA ³Department of Anatomy, Faculty of Dentistry, Mahidol University, Bangkok, Thailand ⁴Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, Washington, USA ⁵Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, South Korea ⁶Department of Chemistry and the Graduate School of Nanoscience and Technology, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea ⁷Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA ⁸Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA ⁹Center for Cardiovascular Biology, University of Washington, Seattle, Washington, USA

[#] These authors contributed equally to this work.

Abstract

Despite possessing substantial regenerative capacity, skeletal muscle can suffer from loss of function due to catastrophic traumatic injury or degenerative disease. In such cases, engineered tissue grafts hold the potential to restore function and improve patient quality of life.

Requirements for successful integration of engineered tissue grafts with the host musculature include cell alignment that mimics host tissue architecture and directional functionality, as well as vascularization to ensure tissue survival. Here we have developed biomimetic nanopatterned

[#] Co-corresponding authors: Deok-Ho Kim, PhD, Associate Professor, Department of Bioengineering, University of Washington, Box 355061, Seattle, WA 98195, Phone: 206-616-1133, Fax: 206-685-3300, deokho@uw.edu, Morayma Reyes, MD, PhD, Director of Hematology Labs, Department of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Moses Division, Central 301, Bronx, NY 10467, Phone: 718-920-2964, Fax: 718-881-2666, mreyesgi@montefiore.org.

Supporting Information Available: Topographical characterization (SEM and AFM) of nanopatterned substrates post-functionalization; high-resolution carbon, nitrogen, and phosphorus XPS scans of SIP-functionalized substrates; fluorescence measurements of functionalized substrates and supernatant over 10 days' incubation; water contact angle measurements of functionalized and non-functionalized substrates; representative live-cell fluorescent videos of contracting myotubes; expression of SIP1 in cells from *Pax7CreERT^{+/+}* x *SIP1 flox^{+/+}* mice relative to those from wild-type mice; representative images of cultures stained for cleaved caspase-3 and quantification; representative images of cultures stained for ceramide and CerS2; primer sequences used for genotyping the transgenic mouse lines generated for this study. This material is available free of charge via the internet at <http://pubs.acs.org>.

Disclaimer

The views expressed are those of the author(s) and do not reflect the official policy or position of the U.S. Army Medical Department, Department of the Army, Department of Defense or the U.S. Government.

poly(lactic-co-glycolic acid) (PLGA) substrates conjugated with sphingosine-1-phosphate (S1P), a potent angiogenic and myogenic factor, to enhance myoblast and endothelial maturation. Primary muscle cells cultured on these functionalized S1P nanopatterned substrates developed a highly aligned and elongated morphology, and exhibited higher expression levels of myosin heavy chain, in addition to genes characteristic of mature skeletal muscle. We also found that S1P enhanced angiogenic potential in these cultures, as evidenced by elevated expression of endothelial-related genes. Computational analyses of live-cell videos showed a significantly improved functionality of tissues cultured on S1P-functionalized nanopatterns as indicated by greater myotube contraction displacements and velocities. In summary, our study demonstrates that biomimetic nanotopography and S1P can be combined to synergistically regulate the maturation and vascularization of engineered skeletal muscles.

Keywords

skeletal muscle; vascularization; nanotopography; sphingosine-1-phosphate; tissue engineering

The loss of skeletal muscle function and volume due to traumatic injury and myopathies such as muscular dystrophy is a significant healthcare problem for which there are currently few interventions.^{1–3} Tissue grafts have shown potential in animal models for restoring damaged or wasted muscles. However, autologous and allogeneic tissue grafting is often associated with detrimental effects such as donor site morbidity or long-term immunosuppression⁴. Likewise, although stem cell-based therapies have shown some promise for improving patient outcomes,^{5–7} such techniques are associated with poor survival, maturation and functional integration of transplanted cells.^{8–11} To address these shortcomings, tissue engineering approaches have been extensively investigated,^{12, 13} with the overarching goal of generating tissues *in vitro* that are capable of restoring function to diseased or injured muscles when engrafted *in vivo*.

Skeletal muscle is comprised of dense, multinucleated muscle fibers that are anisotropically oriented to allow for longitudinal contraction and force generation. As such, one of the most important requirements for engineering functional skeletal muscle tissues is the recapitulation of this highly-organized structure. Muscle extracellular matrix (ECM) architecture has been found to influence cellular behavior and processes critical for overall tissue function. Ultrastructural analysis has revealed that muscle ECM is comprised of highly aligned collagen fiber bundles that feature widths of several hundred nanometers.^{14, 15} Advances in micro- and nanofabrication techniques have led to the development of substrates or scaffolds that mimic these structures, and studies have shown that substrates with biomimetic nanotopographies can induce the formation of ordered muscle tissue *in vitro* in a physiologically-relevant manner by influencing both cellular organization and maturation.^{16–18}

Skeletal muscle is a metabolically demanding tissue, which necessitates a high degree of vascularization. Consequently, engineered muscle should also meet this requirement, particularly if the eventual goal of generating 3D tissue constructs is to be realized. Additionally, vascularization improves cell survival upon implantation by promoting blood

perfusion and in turn reducing apoptosis.^{19, 20} To date, most approaches for generating vascularized tissues have revolved around the use of one or multiple angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) that are delivered *via* scaffolds or integrated depots such as microspheres.^{21–25} Although significant progress has been achieved with these methods, many challenges remain. The use of angiogenic growth factors has proven to be effective at inducing vascularization, although some of these factors have been shown to repress myogenesis.^{26, 27} In addition, the use of recombinant growth factors can be inefficient, as their high cost may mitigate further development or their application for large scale implants.

In this study, we developed an approach for engineering vascularized and more mature skeletal muscle in which biodegradable and biomimetically nanopatterned substrates were conjugated with sphingosine-1-phosphate (S1P), a sphingolipid G-protein-coupled receptor ligand known to have potent angiogenic and myogenic effects.^{28–31} Use of this small molecule agonist is advantageous for modulating both processes and obviates the need for multiple growth factors, greatly simplifying the culture platform. Substrate functionalization was achieved using 3,4-dihydroxy-L-phenylalanine (DOPA), a naturally-occurring amino acid derived from mussel adhesive pads.³² DOPA is capable of forming both strong ionic and covalent bonds with organic molecules through a Michael-addition type reaction without requiring harsh solvents or reagents, and is therefore a process that is likely to maintain the biological activity of S1P. It was hypothesized that the benefits of biomimetic nanotopography and sustained S1P signaling could be harnessed synergistically to induce the formation of structurally organized skeletal muscle tissues that are both mature and vascularized. This capability for generating tissues comprised of functional muscle fibers with a vascular component for nutrient delivery will serve as a promising method for developing therapeutic or investigative platforms.

Results and Discussion

Nanopatterned PLGA substrates were fabricated using capillary force lithography (CFL), a well-established and simple method that allows for the reproducible fabrication of substrates with high-fidelity nanoscale features across centimeter length scales (Figure 1a).³³ In this study, substrates featured aligned ridges and grooves that were 800 nm wide, as this nanotopography best mimicked native tissue ECM, and was previously shown to induce beneficial maturation effects on primary myoblasts.¹⁷ PLGA substrates were then placed in a solution comprised of soluble S1P and DOPA, thereby utilizing a “one-pot” functionalization scheme, the substrates could then be coated with the sphingolipid in a simple and effective manner. Surface functionalization with S1P did not negatively affect the patterned nanotopography, as scanning electron microscope (SEM) and atomic force microscopy (AFM) imaging revealed the maintenance of high pattern fidelity (Figure S1 in Supporting Information). Additionally, successful functionalization of substrates was confirmed using X-ray photoelectron spectroscopy (XPS), where nitrogen, phosphorous, and C-N bond peaks, characteristic of the S1P molecule, were present in conjunction with an attenuation of O-C=O and C=O bond peaks associated with the underlying PLGA (Figure 1b, Figure 2 in Supporting Information). To determine whether bound S1P would degrade

over time in cell culture conditions, PLGA substrates were functionalized with fluorescein-S1P and incubated at 37°C for 10 days in PBS. PBS supernatant was collected throughout the 10-day period and their fluorescence, as well as that of the substrates at the beginning and end of the experiment, were measured using a fluorescent plate reader. It was found that substrate fluorescence was significantly greater than that of PLGA without S1P, and that their fluorescence values remained unchanged over time, while supernatant fluorescence remained at levels identical to that of ordinary PBS (Figure S3 in Supporting Information). These results are indications that the S1P attached to substrates was not significantly degrading over this timeframe and under typical cell culture conditions.

From a scaffold design and engineering aspect, our results provide important insights into the utilization of DOPA-mediated chemistries for functionalizing synthetic materials with bioactive ligands. In our approach, a one-pot method where S1P and DOPA were added simultaneously to the substrates was used, as opposed to a sequential deposition of a DOPA coating followed by S1P conjugation to this layer. In theory, by using the one-pot technique, S1P is better able to form conjugates with free DOPA, thereby allowing for a denser packing of S1P molecules on a substrate. While others have reported success in functionalizing surfaces using this technique with dopamine,^{34, 35} this study demonstrates the viability of one-pot functionalization when using DOPA. Of particular significance is the ability to utilize this technique to immobilize a lipid on a non-flat polymer-based substrate, which is a non-trivial task.³⁶ For example, when using conventional techniques for depositing biomolecules on nanopatterned substrates, such as microcontact printing, it is often difficult to ensure that the surface coverage of both ridges and grooves is achieved. Moreover, use of this DOPA-based technique allowed for the technically-challenging functionalization of a hydrolytically-degradable polymer (PLGA) with a poorly water-soluble biomolecule (S1P) under conditions that did not adversely affect the lipid's biological function.

Although the detailed mechanism for DOPA-mediated functionalization is still under investigation, the chemistry of catechol groups was recently demonstrated, and this mechanism may be involved in the attachment of S1P's α -amine to PLGA's catechol side group.³⁷ This would allow the long acyl chain and polar headgroup of S1P to remain free to interact with S1P receptors. Specifically, the phosphonate headgroup can be surrounded by a ring of positively-charged polar residues provided by the receptor's capping N-terminal capping helix and helices III and VII, and the acyl chain can fully extend into the receptor's hydrophobic pocket with stable hydrophobic interactions.^{38, 39} Indeed, water contact angle measurements of substrates with and without S1P revealed that the functionalized substrates featured a more hydrophobic surface, with an average water contact angle of $75.34^\circ \pm 2.17^\circ$, compared to $62.54^\circ \pm 2.29^\circ$ for bare PLGA (Figure S4 in Supporting Information). However, while this data is indicative of S1P acyl chain integrity, it does not exclude the possibility that some degradation of the polar headgroup still occurs.

In order to distinguish myogenic cells from other populations present in skeletal muscle, we utilized the *Pax7-CreERT2* allele which is definitively expressed by the majority of satellite cells.^{40–43} Transgenic mice harboring the *Pax7-CreERT2* and *mT/mG flox* alleles were generated to induce irreversible labeling of *Pax7* expressing myogenic cells with membrane localized GFP.⁴⁴ In this dual fluorescence fate-mapping model, non-myogenic cells were

distinguishable by their expression of membrane localized tdTomato. Primary muscle cells from these mice were isolated from mouse limb muscles *via* enzymatic digestion and seeded onto flat and patterned substrates conjugated with S1P at varying concentrations (0, 50, 100, 175, and 250 μ M). Cultures were maintained for 10 days and fixed for imaging or collected for gene expression analysis. These cultures were comprised of a heterogeneous mononuclear cell population that included satellite cells and their progeny, endothelial cells, and fibroblasts. As previously observed,¹⁷ nanopatterned substrates induced a greater degree of structural organization in the form of aligned myotubes (Figure 2a). These substrates also appeared to enhance the myogenic potential of cultured progenitor cells as a greater number of GFP⁺ cells were observed in the patterned environment (Figure 2b). Interestingly, myogenesis appeared to be S1P dose-dependent, as myotube count peaked at 175 μ M S1P. These trends also held true when examining the fusion index (number of nuclei per myotube), with topography and S1P imparting a synergistic effect on myotube formation as a result of myoblast fusion. However, S1P at the highest concentration of 250 μ M appeared to have a detrimental effect on myogenesis, as GFP⁺ cell count and fusion index decreased sharply on both flat and patterned substrates under this condition. To further examine the maturation of the engineered muscle tissue, cultures of primary muscle cells from wild-type (WT) mice were stained for myosin heavy chain type I (MHC), an isoform of slow MHC expressed by mature muscles.⁴⁵ A significantly greater number of MHC-I⁺ myotubes was observed on patterned substrates *versus* flat with most S1P concentrations. The greatest number of differentiated myotubes observed on patterned substrates was also with 175 μ M of S1P, followed by a sharp decrease at 250 μ M S1P (Figure 3a, b).

Subsequently, we analyzed the transcriptional profile of myogenic regulatory factors to understand the mechanisms of S1P on myotube maturation that occurred in a dose-dependent manner. The relative expression levels in cultured cells of several genes that spanned the spectrum of myogenic development were quantified using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analyses (Figure 3c). As aforementioned, *Pax7* plays a critical role in the proper function of satellite cells and is therefore a well-established indicator of immature skeletal precursors (satellite cells). Examination of this gene revealed a significantly greater expression level in cells cultured on patterned substrates as compared to their flat substrate counterparts, regardless of S1P concentration. S1P-mediated expression also appeared to follow the previously observed biphasic trend. However, for patterned substrates, relative expression peaks at 100 μ M S1P, rather than at 175 μ M. In contrast to *Pax7*, which is specific for undifferentiating muscle precursors that can self-renew, *Myf5* is expressed in differentiating myoblasts and immature myocytes^{46–48}. We observed that cells cultured on flat substrates exhibited greater expression levels of this gene compared to those cultured on patterned substrates, with no apparent differences due to S1P. The expression of *MyoD*, *MyoG* (myogenin) and *Myh15* (myosin heavy chain 15), which are expressed in late-stage or terminally differentiated muscle cells,^{49, 50} was greater in cells not only on patterned substrates, but also significantly in cells on substrates with 175 μ M S1P, regardless of underlying topography (Figure 3c). Since a peak in expression of markers for more mature cells at 175 μ M S1P was observed, it is plausible that this increase in maturation led to a corresponding lower expression of *Pax7*

at this concentration of S1P. In all examined genes, there was a drastic decrease in expression levels in cells cultured on substrates functionalized with 250 μ M of S1P.

Although the enhancement of myogenesis and maturation of the engineered skeletal muscle cultures was demonstrated with the aforementioned analyses, molecular markers of myogenesis are not direct indicators of muscle function. Thus, experiments were conducted to determine whether the maturation observed due to synergistic signaling from S1P and nanopatterning translated to improvements in myotube function. Using a correlation-based contraction quantification (CCQ) MATLAB script developed by our lab,⁵¹ bright-field microscopy videos of contracting myotubes were analyzed. The maturation effects of biomimetic nanopatterning led to a corresponding improvement in myotube function, as myotubes on these substrates featured an average contraction displacement of 1.11 ± 0.13 μ m, while those on flat substrates had an average contraction displacement of 0.79 ± 0.11 μ m. Myotubes on nanopatterned substrates functionalized with 175 μ M S1P exhibited an average contraction displacement of 3.37 ± 0.39 μ m, while those cultured on functionalized flat substrates had an average displacement of 2.18 ± 0.36 μ m (Figure 4a). The addition of S1P led to a significant increase in displacement values for myotubes on both flat and patterned topographies, although patterning still led to a functional maturation advantage. A similar trend was observed in regard to the contraction velocities of myotubes, where significant increases occurred when nanotopography and S1P were present. Representative of the two ends of the spectrum, myotubes on nanopatterned substrates functionalized with 175 μ M S1P had an average contraction velocity of 9.11 ± 1.18 μ m/s, while myotubes on non-functionalized flat substrates had an average contraction velocity of 1.44 ± 0.34 μ m/s (Figure 4b).

S1P and nanotopography effects on myotube Ca^{2+} handling capabilities were examined by generating transgenic mice in which *Pax7CreERT2* expressing cells and their progeny would express GCaMP3, a well-characterized GFP-based calcium indicator for imaging Ca^{2+} dynamics in cells.^{52, 53} Once more, primary muscle cells were cultured on flat and patterned substrates with and without 175 μ M S1P and imaged after 10 days with fluorescence live cell microscopy. Myotubes that had formed from these GCaMP3-expressing progenitor cells were observed to fluoresce as they spontaneously contracted (Videos 1 & 2 in Supporting Information), and the fluorescence intensity of these myotubes was tracked and plotted over time. Interestingly, the contractile rhythm of myotubes differed based on culture conditions, where those on flat substrates contracted irregularly, while those on nanopatterned substrates with S1P exhibited more regular and consistent contractions (Figure 4c). Quantification of the average fluorescence intensities revealed that myotubes cultured with S1P on nanopatterned substrates exhibited significantly greater levels of fluorescence corresponding to calcium ion flux, and thus an indication of improved calcium handling (Figure 4d). Combined, the results of contraction and calcium dynamics analyses show that the increased expression of skeletal muscle maturation markers due to the combination of topographical and S1P signaling cues led to a corresponding enhancement of the engineered tissue's functional capabilities.

Primary cell cultures from wild-type mice were simultaneously stained with BS1 lectin, an endothelial cell marker⁵⁴ (green), and MHC (red) to examine the neovascularization

potential of S1P-functionalized substrates (Figure 5a). The potency of S1P as angiogenic factor was observed with increasing concentrations corresponding to a greater number of BS1⁺ cells, regardless of topography. In contrast to myogenic indicators that peaked with 175 μ M of S1P, the number of BS1⁺ cells was greatest with 250 μ M of S1P (Figure 5b). On some of the 175 μ M patterned substrates, BS1⁺ cells appeared to organize themselves along the axis of myotubes. To confirm that the dose dependent increase of BS1⁺ cells corresponded with a presence of active endothelial cells, we examined the transcription levels of angiogenic markers. The expression of genes related to endothelial adhesion (PECAM, *CD31*), function (von Willebrand factor, *vWF*), integrity (VE-cadherin, *Ve-Cad*), and vascular tone regulation (endothelial nitric oxide synthase, *eNOS*) were assessed quantitatively (Figure 5c). A correlation between S1P concentration and detection of endothelial transcripts was observed, with the greatest and most significant expression levels found in cells cultured on substrates functionalized with 250 μ M S1P. In general, topography did not appear to play a significant role in regulating vascularization, although qualitative alignment of vascular cells with myotubes was only observed on patterned substrates.

To gain insight on the molecular mechanism by which S1P, in combination with nanotopography, modulates myogenesis, we examined the role of S1P receptor 1 (S1P₁) in myogenic cells. Although S1P signaling in skeletal musculature is highly complex and confers a variety of functions that are mediated mainly by S1P receptors 1 through 3,⁵⁵ S1P₁ was chosen due to it being the most highly expressed in satellite cells during skeletal muscle regeneration, as well as in primary myoblasts cultured on nanopatterned substrates functionalized with 175 μ M S1P (Figure S5 in Supporting Information).^{56, 57} We employed tamoxifen inducible genetic deletion of S1P₁ specifically in satellite cells by utilizing *Pax7CreERT2* mice that were homozygous for the *S1P₁ flox* allele.⁵⁸ To validate the effectiveness of the Cre-lox gene ablation, primary muscle cells from these and WT mice were cultured onto flat and patterned substrates functionalized with either no S1P or with 175 μ M S1P for 10 days. Using qRT-PCR analysis, it was found that the expression of S1P₁ was significantly reduced in cells from *Pax7CreERT^{+/−} x S1P₁ flox^{+/+}* mice (Table S1 in Supporting Information). Staining for MHC in myotubes formed from these cells revealed no significant difference in expression despite the presence of S1P, while patterned substrates induced greater expression of this protein compared to flat substrates (Figure 6a, b). Furthermore, quantitative genetic analysis also revealed that topographical cues were still able to upregulate *Pax7* and *MyoG* expression, while S1P did not (Figure 6c). Since S1P₁ was only knocked out in the myogenic cells that would eventually differentiate and form myotubes, the effects of S1P on endothelial cell maturation should be maintained. This was confirmed with qRT-PCR analysis of markers for vascular development (*CD31*, *Ve-Cad*), which showed significant upregulation independent of substrate topography when these cells were exposed to S1P (Figure 6d).

The significance of sphingolipids and the extent of their signaling has yet to be fully elucidated,⁵⁹ and S1P in particular has been found to play a role in the regulation of a variety of critical cell processes, such as division, survival, migration, and adhesion,^{60–63} with recent studies suggesting that S1P is also involved in skeletal muscle regeneration. Under homeostatic conditions, low circulation concentrations of S1P (~ 2 μ M) can be found in mammalian plasma; however, upon focal muscle injury, plasma S1P levels can increase by

up to 50%.⁶⁴ There are strong indications that this increase in S1P synthesis and subsequent availability as a circulating ligand in response to injury is required to mediate the migration, activation, and entry of satellite cells into the cell cycle in order to differentiate and form new muscle.^{30, 31, 56, 65} Our results appear to support these findings, as myogenic progenitor activation and differentiation significantly improved as S1P concentration increased, with a functionalization concentration of 175 μ M eliciting a peak response. The finding of a larger presence of *Pax7*⁺ cells present on patterned substrates conjugated with this concentration of S1P suggests that there is a greater induction of immature myoblast proliferation, or perhaps that there is a stable population of progenitor cells present that would enable the long-term differentiation and restoration of lost or damaged tissue. At the same time, lower expression levels of *Myf5* on patterned substrates, regardless of S1P, is an indication that in addition to the maintenance or recapitulation of the satellite cell niche, biomimetic nanotopographies also induce those cells that do become activated to readily differentiate towards the formation of mature skeletal muscle tissue. However, the expression of genes and proteins indicative of late stage myogenic maturation once again increased with S1P, and this corresponded with improved tissue function in the form of increased myotube contraction displacement and velocity, which can be translated to an increase in contractile force. The irregularity of the spontaneous contractions observed in myotubes on flat substrates *versus* those on functionalized patterned substrates is a further indication of the improved contractile machinery development due to nanotopographical and S1P signaling. The improved Ca^{2+} handling of myotubes on functionalized nanopatterned substrates is also a sign of tissue maturation attributed to enhanced myogenic development due to S1P, as S1P has been shown to increase intracellular calcium levels,⁶⁶ with calcium in turn acting as a mediator of myoblast differentiation.⁶⁷

By mimicking the nanotopographical cues that would normally be seen by myoblasts and satellite cells *in vivo*, our aim was to recapitulate signaling cascades that would lead to improved functional maturation. While the role of specific mechanotransduction pathways in this process is still being elucidated, it has been demonstrated that Rho GTPases involved in cytoskeletal reorganization positively regulate MyoD expression and skeletal muscle differentiation.⁶⁸ It has also been found that in myoblastic cells, cytoskeletal remodeling and the formation of stress fibers promote the opening of stretch-activated channels and the subsequent increase in Ca^{2+} influx.^{69, 70} This is reflected in the data shown in Figure 4, and since Ca^{2+} is an important second messenger for skeletal muscle differentiation, this is another potential mechanism for nanotopography-mediated maturation. Studies have also suggested that the PI3K/Akt pathway is involved in contact guidance and mechanotransduction signaling, and that activation of this pathway leads to skeletal muscle hypertrophy and myogenesis.^{71, 72} The benefits of biomimetic nanotopography is perhaps most apparent in the S1P₁ flox-out experiments where nanotopographical cues were still able to induce myotube formation, cellular alignment, and upregulated expression of late-stage maturation muscle maturation markers, even as the myogenic effects of S1P were being mitigated. It is possible that as part of the downstream effects of this mechanotransduction signaling, S1P is produced and secreted by the myogenic cells themselves *via* sphingosine kinases to induce S1P-mediated effects downstream.⁶⁵ To investigate this further, the relative expression levels of sphingosine kinase 1 (*Sphk1*),

sphingosine kinase 2 (*Sphk2*), and sphingosine phosphatase 1 (*Sgpp1*) in both primary murine muscle cells and C2C12 myoblasts cultured on flat and patterned substrates with and without S1P were analyzed. With the exceptions of an upregulation of *Sphk1* in primary myoblasts on substrates with no S1P and an upregulation of *Sgpp1* in C2C12 myoblasts on patterned substrates with S1P, no other significant differences in expression levels were observed (Figure S6 in Supporting Information). The results suggest that kinase activity and S1P synthesis is unaffected by nanotopographical cues, and that in some cases, the lack of exogenous S1P induces an increase in the production of endogenous S1P. Furthermore, if the bulk of the maturation responses observed in this study were due to endogenously-formed S1P, we should expect to see similar levels of expression of maturation markers and functional capabilities in all cultures in which nanopatterning was present. Instead, we see a significant upregulation of these markers in addition to improvements in myotube function at higher concentrations of exogenous substrate-bound S1P. These results are thus an indication that there is a synergistic effect on functional maturation that is achieved when cells are subjected to both S1P signaling and nanotopographical cues, and that this effect is greatly enhanced by the S1P-functionalized nanopatterned substrates utilized in this study.

While the most effective concentration of S1P for muscle maturation in this study was found to be orders of magnitude greater than physiological levels, this may be a function of a situation in which the presented ligands are bound to a substrate, rather than being freely available in solution as it is the case *in vivo*. This could in fact provide an additional benefit when these muscle sheets are implanted. As the biodegradable substrates are broken down over time, bound S1P would be released locally and induce prolonged regeneration that would further enhance tissue development and function, even in dystrophic muscles.⁵⁷

In addition to inducing myogenic differentiation, S1P signaling has long been acknowledged to play a key role in vascular development and angiogenesis. Specifically, it has been shown by others that vascular endothelial cells cultured with S1P exhibited increased motility, eNOS enzyme activity, and cell barrier integrity, leading to a corresponding increase in tube formation over time.^{28, 73–75} Additionally, disruption of S1P signaling *in vivo* results in blood flow dysregulation and vascular leakage due to junctional destabilization resulting from VE-cadherin mislocalization.^{58, 76, 77} These pro-vascularization effects were also seen in this study with the increased expression of genetic markers for not only endothelial cell maturity, but also for vessel formation and stabilization. Furthermore, once implanted, the presence of S1P could also induce the migration of endothelial and vascular smooth muscle cells present in the host tissue to the implantation site and contribute to the formation of neovessels.^{29, 78} In addition to the long-term functional and survival benefits of generating vascularized skeletal muscle tissues, the presence of mature endothelial cells can also assist with myogenic development, since the secretion of VEGF from these cells has been shown to stimulate myotube hypertrophy and further improve myogenic differentiation.⁷⁹ Differentiating myogenic cells also secrete VEGF, and this could induce pronounced localized angiogenesis, thus creating a positive feedback loop in which reciprocal interaction between these two cell types can support continued angio-myogenesis.⁸⁰ This is perhaps best illustrated by the close juxtaposition of endothelial cells with myotubes present on nanopatterned substrates functionalized with 175 μ M, which was shown to induce the greatest degree of myogenic differentiation and maturation. Indeed, when cells were cultured

on flat and patterned substrates functionalized with 175 μM S1P were fed with media supplemented with 5 μM of cabozantinib (XL184), a potent VEGF receptor 2 (VEGFR2) inhibitor, markers for late-stage and terminal skeletal muscle maturation (*MyoG*, *Myh15*) were downregulated in comparison to cultures without VEGFR2 inhibition (Figure 7a). However, these markers were more expressed in cells cultured on nanopatterned substrates than in cells on flat substrates, indicating that mechanotransduction cues were still exerting an effect. Meanwhile, the expression of markers of vascular endothelial maturation (*eNOS*, *Ve-Cad*) was significantly downregulated in cultures with cabozantinib (Figure 7b). Taken together, these results suggest that inhibiting VEGF function in these co-cultures reduces the benefits of engineering an environment in which mutually beneficial maturation can occur as it does *in vivo*.

Interestingly, it was observed that there was an apparent biphasic dependence of myogenesis on S1P concentration, and that this trend did not carry over to vascular development. In fact, at the highest concentration tested (250 μM), the number of myoblasts and myogenic progenitors were greatly reduced in number and some even appeared to be apoptotic. Ceramide, a metabolite of S1P that is produced by the conversion of sphingosine *via* ceramide synthases (CerS), is generally associated with growth arrest and cell death.^{81–83} Since this conversion is reversible, it has been proposed that it is the relative levels of these two lipid signaling molecules in response to external stimuli that determines cell fate, and thus acts as a “sphingolipid rheostat”.^{83, 84} Therefore, with the production of a large amount of ceramide at 250 μM S1P, this balance may have been shifted towards a pro-apoptotic state in myoblasts, thereby negating the beneficial myogenic effects of S1P. Immunostaining of cultures at this concentration of S1P for cleaved caspase-3, a marker for apoptosis, revealed that the percentage of apoptotic cells is in fact significantly greater than in controls (Figure S7 in Supporting Information). However, it has been found that the activity of ceramide synthase 2 (CerS2) is inhibited by S1P, and that the distribution of CerS2 is greatest in highly-vascularized organs such as the liver and kidney.⁸⁵ It is then plausible that this inhibited activity of CerS2 in the cultured endothelial cells decreases the conversion rate of S1P to ceramide, and thus maintains the pro-angiogenic response of these cells to increased S1P stimulation. To further explore this hypothesis, primary cells were sorted into myoblast and endothelial cell populations before being cultured on substrates functionalized with 250 μM S1P and subsequently immunostained for ceramide and CerS2. In addition to displaying a more apoptotic morphology, ceramide accumulation was found to be significantly greater in myoblasts than in endothelial cells. At the same time, CerS2 expression was found to be greater in endothelial cells which correlates with other findings in literature (Figure S8 in Supporting Information).⁸⁶ This data thus suggests that the inhibition of this specific synthase in endothelial cells is indeed helping with the shifting of the sphingolipid rheostat away from the overwhelming ceramide synthesis and resulting apoptosis seen in the myogenic cell population.

Conclusions

While the capabilities of biomimetic nanotopographies on inducing cellular maturation have been reported on previously,^{17, 87} the incorporation of the sphingolipid S1P as a ligand for simultaneously enhancing both the myogenic and neovascularization potential of cultured

cells is an important aspect of this work. The resulting tissues were structurally ordered, and at higher S1P concentrations, were comprised of numerous differentiated and contracting myotubes, along with a sub-population of *Pax7*-expressing muscle precursors. Additionally, the increased expression levels of endothelial markers in these tissues is an indication of *in vitro* vascular development and improved potential for tissue integration and survival. In future work, by utilizing cell-sheet fabrication techniques that enable the generation of highly-ordered 3D tissues in a scaffold-free manner⁸⁸ and subsequently culturing these multi-layered constructs in the presence of S1P, it would be possible to create 3D skeletal muscle tissues that are primed for continued myogenic development and vascularization once implanted *in vivo*. Aside from their potential application as a form of implantable therapy for treating chronic or traumatic skeletal muscle loss, tissues generated using the techniques reported herein can also be considered as an effective *in vitro* platform for further characterizing the molecular mechanisms behind muscle development, as well as for disease modeling or drug screening.

Methods

Substrate Fabrication.

Flat and nanopatterned substrates were generated using a capillary force lithography (CFL) technique that has been detailed previously¹⁷. Briefly, polyurethane acrylate (PUA; Minuta Technology, Korea), and polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, MI, USA) were first prepared to form the molds and solvent-absorbing sheets, respectively. PUA molds were fabricated by first dispensing PUA precursor onto a patterned silicon wafer master which had been made using standard photolithography techniques, and lightly pressing a polyethylene terephthalate (PET, Skyrol®, SKC Inc., Korea) film (thickness = 75 μm) against the PUA. The PUA precursor spontaneously filled the cavities of the master mold by means of capillary action and was cured by exposure to UV light ($\lambda = 250\text{--}400\text{ nm}$) for approximately 30 s (dose = 100 mJ/cm^2). After this initial curing, the PUA mold was peeled off from the substrate and further exposed to UV light overnight for complete curing. PDMS sheets were made by first combining polymer precursor and curing agent at a mixing ratio of 10:1 and cured at 60°C for 10 hrs before manually cutting prior to use.

To generate the substrates used in this study, a 100 μL drop of 15% w/v PLGA (MW: 50,000 – 75,000, 50:50 lactide:glycolide ratio, Sigma-Aldrich, MO, USA) dissolved in chloroform was dispensed onto a clean glass coverslip, and a PDMS sheet was placed on top of the polymer solution. Slight pressure ($\sim 10\text{ kPa}$) was applied evenly on the PDMS for 5 min before the sheet was removed. The PLGA-coated coverslip was then placed onto a hot plate preheated to 120°C for 5 min to allow any residual solvent to evaporate. A nanopatterned PUA mold was then placed on top with constant pressure ($\sim 100\text{ kPa}$) applied for 15 min before the entire assembly was removed from heat and allowed to cool to room temperature. The mold was carefully peeled off and the nanopatterned PLGA substrate is stored under desiccation until ready for use. For this study, substrates with $800 \times 800 \times 600\text{ nm}$ (groove width $\times$ ridge width $\times$ groove depth) feature sizes were used. Flat PLGA substrates were fabricated by skipping the patterning steps, and were also stored under desiccation.

Substrate Functionalization with S1P.

Fabricated PLGA substrates were functionalized with sphingosine 1-phosphate (S1P; Cayman Chemical, MI, USA) or fluorescein-S1P (Echelon Biosciences, UT, USA) using 3,4-dihydroxy-L-phenylalanine (DOPA; Sigma Aldrich). A 2 mg/mL working solution of was generated by dissolving DOPA in 10 mM tris(hydroxymethyl)aminomethane (Tris; Fisher Scientific, NH, USA) buffer with a pH of 8.5. DOPA working solution was combined with a 500 μ M S1P stock solution for each sample to achieve the appropriate S1P concentration. Samples were then incubated at room temperature overnight on a rocker. Afterwards, the DOPA-S1P solution was aspirated and substrates were washed three times with PBS before being dried using nitrogen gas. Substrates not functionalized with S1P were incubated with DOPA only.

Scanning Electron Microscopy (SEM).

S1P-functionalized nanopatterned substrates were sputter-coated with Au/Pd alloy prior to imaging, which was accomplished using a scanning electron microscope (Sirion XL30, FEI, OR, USA) at an accelerating voltage of 5 kV.

Atomic Force Microscopy (AFM).

An atomic force microscope (Dimension Icon-PT, Bruker, MA, USA) was used to measure the topography of nanopatterned substrates post-functionalization. The AFM was operated in non-contact mode with scan frequency of 0.5 Hz, and images were taken in 256×256 pixel resolution over a $10 \mu\text{m} \times 10 \mu\text{m}$ area.

X-Ray Photoelectron Spectroscopy (XPS).

All XPS spectra were taken using a Surface Science Instruments S-probe spectrometer, and peak areas were determined using Service Physics ESCA2000A Analysis Software. X-ray spot size was approximately 800 μm , and pass energy for survey and high-resolution spectra was 150 eV and 50 eV, respectively. The take-off angle was approximately 55° , which translates to a sampling depth of approximately 50 Å. Three spots were analyzed on each PLGA sample (bare and functionalized).

Water Contact Angle Measurements.

A 10 μL droplet of dH_2O was deposited onto substrates with DOPA and DOPA+S1P. Droplets were imaged and their contact angles with the substrates measured using a goniometer (FTA200, First Ten Ångströms, VA, USA). Six samples of each group were used for these measurements.

Transgenic Mouse Generation.

For all experiments in which primary muscle cells from transgenic mice were used, we utilized mice harboring the tamoxifen-inducible knock-in/knock-out *Pax7CreERT2* allele⁸⁹. These were mated with mice homozygous for the *mT/mG* flox, heterozygous for the *GCamp3* flox, and homozygous for the *S1P₁* receptor to generate each respective Cre-lox system^{44, 53, 58}. Reporter mice required only one generation to produce genotypes of *Pax7CreERT^{+/+} x mT/mG^{+/-}* or *Pax7CreERT^{+/+} x GCamp3^{+/-}*. *Pax7CreERT^{+/+} x S1P₁ flox*

$+/+$ mice were achieved within 3 generations by crossing F1 *Pax7CreERT^{+/+}* x *SIP1 flox^{+/+}* with unrelated *SIP1 flox^{+/+}* animals. All mouse models were acquired from Jackson labs with the following catalog numbers: 012476, 007575, 014538, and 019141. Genotyping was accomplished using 1–2 mm tail clips that per collected and frozen in 1.5 mL Eppendorf tubes at -20°C until ready for processing. Genomic DNA was extracted by boiling tail snips at 95°C in 75 μL of 50 mM NaOH for approximately 1 hr, with vortexing every 15 minutes. Reactions were then neutralized by adding 25 μL 1M tris-HCl pH 6.8 and then samples were centrifuges at 13,000 g for 2 mins. Polymerase chain reaction (PCR) analysis was conducted using 1 μL of template from our extraction buffer in a final reaction of 20 μL with the Bioline 2x Master mix following the manufacturer's instructions. Primer pairs and polymerase reaction parameters are listed in Table S2 in Supporting Information. NIH guidelines for the care and use of laboratory animals (NIH Publication #85–23 Rev. 1985) were observed throughout this study.

Cell Isolation and Culture.

Hind limb muscle mononuclear cells used in culture were isolated as previously described^{17, 90}. Briefly, three days prior to tissue harvesting, the tibialis anterior (TA), gastrocnemius and quadriceps muscles of both limbs in each mouse were injected with a 10 nM solution of cardiotoxin (CTX) from *Naja mossambica* (Sigma Aldrich) dissolved in water. TA were injected with 50 μL , and gastrocnemius and quadriceps were injected with 100 μL each. Mice were sacrificed 3 days post-injury at the peak of satellite cell activation following CTX injury. The timing of collection was chosen to enrich mononuclear cell isolations with myogenic cells that are otherwise a minority in these skeletal muscles. Previous characterization of cells obtained using this isolation protocol have revealed that of the non-hematopoietic cell types, approximately 32% and 35% were comprised of myogenic and endothelial cells, respectively. The remainder of the cell population was comprised of fibroblasts and other non-myogenic cell types.^{90, 91} Injured muscles were harvested under sterile conditions and cleaned of any fat and tendons and then digested in a buffer containing both collagenase type IV and dispase II (Worthington Biochemical, NJ, USA) for a total of 45 min at 37°C . Cell/tissue mixtures were then transferred to warmed F10 medium (Hyclone, PA, USA) supplemented with 15% horse serum to inhibit enzyme digestion. The mixture was then passed sequentially through cell strainers with 70 μm and 40 μm mesh sizes to remove debris, muscle fibers, and multinucleated cells. Collected mononuclear cells were then seeded onto each respective substrate at a density of 50,000 cells/ cm^2 . Cells were maintained in F10 medium supplemented with 2 μM CaCl_2 , 15% horse serum, and 20 ng/mL mouse basic fibroblast growth factor (bFGF), and media was changed every 4th day of culture. For induction of Cre-lox knock-in/knock-out in cells from transgenic mice, media was further supplemented for the first 4 days of culture with 20 $\mu\text{g/mL}$ 4-hydroxytamoxifen (Sigma Aldrich). For vascular endothelial growth factor receptor 2 (VEGFR2) inhibition studies, media was supplemented with 5 μM cabozantinib (XL184; Selleck Chemicals, TX, USA) dissolved in dimethyl sulfoxide (DMSO).

Fluorescence Activated Cell Sorting.

Isolated primary cells were resuspended in PBS with 1% BSA and incubated with fluorophore-conjugated mouse antibodies for CD31, CD34, CD45, $\alpha 7$ integrin, and Sca1 for

60 minutes at room temperature. Cells were then washed and resuspended in PBS with 2% PBS before being sorted into myogenic and endothelial cell populations as previously described.⁹⁰ Briefly, cells that were CD31⁺/CD45⁻ were sorted as endothelial cells, while cells that were CD31⁻/Sca1⁻/CD34⁺/α7⁺ were sorted as myogenic cells.

Immunostaining and Fluorescence Microscopy.

Cultures for imaging were fixed at day 10 with 4% paraformaldehyde in PBS for 10 minutes at room temperature before permeation with 0.1% Triton-X for 10 minutes. For myosin heavy chain staining, myotubes were incubated overnight at 4°C with purified mouse IgG against myosin heavy chain type I (1:100, BA-D5, Developmental Studies Hybridoma Bank, deposited by Schiaffino, S.), then with rabbit anti-mouse IgG conjugated with Alexa Fluor 647 (1:500 for 1 hour at room temperature). For endothelial cell identification, FITC-conjugated BS1 (1:500 for 1 hour at room temperature, Sigma-Aldrich) was utilized to stain cells for imaging. Staining for apoptosis was achieved using an antibody for cleaved caspase-3 (Cell Signaling Technology, MA, USA) diluted at 1:200. Antibodies for ceramide (Sigma Aldrich) and CerS2 (Boster Biological Technology, CA, USA) were also used at a 1:200 dilution for staining and imaging. F-actin was stained using Alexa Fluor 488-conjugated phalloidin (Invitrogen, CA, USA). All secondary antibodies were utilized at a 1:500 dilution. Nuclei were stained with DAPI (Invitrogen). Stained cells were then imaged using a Zeiss Axiovert 200 widefield fluorescence microscope. Quantitative analysis of images was accomplished using ImageJ software (National Institutes of Health, MD, USA), and were conducted by two blinded researchers independently.

Gene Expression Quantification.

After 10 days of culture, RNA from approximately 1×10^6 cells cultured cells was collected from 10 different cultures using the E.Z.N.A. Total RNA Kit I (Omega Bio-Tek, GA, USA) according to the manufacturer's protocol. Quantity and purity of RNA was determined by 260/280nm absorbance. First-strand cDNA was synthesized from 1μg of RNA using the high capacity cDNA synthesis kit from Applied Biosystems (CA, USA) per manufacturer's protocols using a randomized primer. The relative expression levels of selected genes were obtained using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analyses. cDNA of cultured cells in different condition (10ng) was prepared using the Maxima SYBR Green/ROX qPCR master mix (Thermo Scientific, MA, USA). Reactions were processed by the ABI 7900HT PCR system with the following parameters: 50°C/2min and 95°C/10min, followed by 40 cycles of 95°C/15s and 60°C/1min. Results were analyzed using SDS 2.3 software, and relative expression was calculated using the comparative Ct method. Each sample was run in triplicate reactions for each gene. To examine myogenic differentiation and myogenic potential, *Pax7*, *Myf5*, *MyoD*, *MyoG* (myogenin), and *Myh15* were used as markers, while *CD31*, *Ve-Cad*, *vWF*, and *eNOS* were used as markers for the vascular differentiation of endothelial cells. Primers for the myogenic regulatory factors *Pax7*, *Myf5*, *MyoD* and *MyoG* were as previously reported⁸⁹. Primers used for the vascular related genes *CD31*, *Ve-Cad*, *vWF*, and *eNOS* were also as previously reported⁹². Primer pairs for *Myh15* were designed in-house and were (5'-TGA GCC TAA GAA AAA GCT GGG-3', forward) and (5'-CCA AAA CGC GAA GAG TTG TCA-3', reverse). For validation of the S1P₁ flox-out mouse model, primers used for assessing the expression of

this receptor were as previously reported.⁹³ Primers for *Sphk1*, *Sphk2*, *Sgpp1*, *SIP₁*, *SIP₂*, and *SIP₃* were purchased from Bio-Rad Laboratories, Inc., and used as supplied. *GAPDH* was used as a housekeeping gene and conventional tissue culture polystyrene substrates with no SIP were used as a control in all analyses.

Calcium Imaging and Analysis.

Fluorescent live cell videos at 20X magnification and an excitation wavelength of 488 nm were taken of contracting GCaMP⁺ myotubes. Videos were analyzed for fluorescence intensity using ImageJ. Peak fluorescence values from contracting myotubes were averaged for each condition across at least 20 fields of view. Videos were captured using a Zeiss Axiovert 200 widefield fluorescence microscope.

Correlation-based Contraction Quantification (CCQ).

Bright-field videos of contracting myotubes obtained at 20X magnification were analyzed using a custom MATLAB (MathWorks, MA, USA) script for CCQ that utilizes particle image velocimetry (PIV) and digital image correlation (DIC) algorithms⁵¹. In brief, an initial reference video frame is established and divided into a grid of windows of a set size. Each of these windows is run through a correlation algorithm with a subsequent frame, and any displacement that occurs between frames is converted into a vector map. This map provides contraction angles, and when spatially averaged, contraction magnitudes and velocities. A Gaussian correlation peak with a probabilistic nature is used in the correlation equation, providing sub-pixel accuracy. The bright-field videos analyzed using CCQ were captured using a Nikon TS100 microscope at 30 frames per second.

Statistical Analyses.

All quantitative data is presented as mean $\pm$ standard error of the mean (SEM). One-way ANOVA with Tukey's *post-hoc* multiple comparisons method was used to analyze data sets that include more than two experimental groups, while a Student's *t*-test was used to compare data sets looking at only two variables. In all analyses, a *p* value less than 0.05 was considered significant and *n* was defined by the number of discrete cultured substrates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work was supported by National Institutes of Health grants R21AR064395 and R01NS094388 (to D.-H. K.), and Muscular Dystrophy Association grants MDA 255907 (to D.-H. K.) and MDA 277543 (to M. R.). This work was also supported by a University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging Genetic Approaches to Aging Training Grant Fellowship T32AG000057 (to N. I.), and a Howard Hughes Medical Institute/University of Washington Molecular Medicine Scholarship (to J. H. T.). The authors would like to thank Dr. Dan Graham at the University of Washington's National ESCA and Surface Analysis Center for Biomedical Problems (NESAC/BIO; NIH P41EB002027) for his assistance with the XPS analysis of functionalized substrates. The authors would also like to thank Eve Byington and Austin Chen for their technical assistance in this study.

References

1. Kalyani RR; Corriere M; Ferrucci L, Age-Related and Disease-Related Muscle Loss: The Effect of Diabetes, Obesity, and Other Diseases. *Lancet Diabetes Endocrinol* 2014, 2, 819–829. [PubMed: 24731660]
2. Puthucherry ZA; Rawal J; McPhail M; Connolly B; Ratnayake G; Chan P; Hopkinson NS; Phadke R; Dew T; Sidhu PS; Velloso C; Seymour J; Agley CC; Selby A; Limb M; Edwards LM; Smith K; Rowleron A; Rennie MJ; Moxham J; Harridge SD; Hart N; Montgomery HE, Acute Skeletal Muscle Wasting in Critical Illness. *J. Am. Med. Assoc* 2013, 310, 1591–1600.
3. MacKenzie EJ; Jones AS; Bosse MJ; Castillo RC; Pollak AN; Webb LX; Swiontkowski MF; Kellam JF; Smith DG; Sanders RW; Jones AL; Starr AJ; McAndrew MP; Patterson BM; Burgess AR, Health-Care Costs Associated with Amputation or Reconstruction of a Limb-Threatening Injury. *J. Bone Joint Surg. Am* 2007, 89, 1685–1692. [PubMed: 17671005]
4. Muramatsu K; Doi K; Kawai S, The Outcome of Neurovascularized Allogeneic Muscle Transplantation Under Immunosuppression with Cyclosporine. *J. Reconstr. Microsurg* 1994, 10, 77–81. [PubMed: 8182568]
5. Collins CA; Olsen I; Zammit PS; Heslop L; Petrie A; Partridge TA; Morgan JE, Stem Cell Function, Self-Renewal, and Behavioral Heterogeneity of Cells from the Adult Muscle Satellite Cell Niche. *Cell* 2005, 122, 289–301. [PubMed: 16051152]
6. Montarras D; Morgan J; Collins C; Relaix F; Zaffran S; Cumano A; Partridge T; Buckingham M, Direct Isolation of Satellite Cells for Skeletal Muscle Regeneration. *Science* 2005, 309, 2064–2067. [PubMed: 16141372]
7. Sacco A; Doyonnas R; Kraft P; Vitorovic S; Blau HM, Self-Renewal and Expansion of Single Transplanted Muscle Stem Cells. *Nature* 2008, 456, 502–506. [PubMed: 18806774]
8. Burdzinska A; Gala K; Kowalewski C; Zagodzón R; Gajewski Z; Paczek L, Dynamics of Acute Local Inflammatory Response After Autologous Transplantation of Muscle-Derived Cells into the Skeletal Muscle. *Mediators Inflamm* 2014, 2014, 482352. [PubMed: 25242868]
9. Cosgrove BD; Sacco A; Gilbert PM; Blau HM, A Home Away from Home: Challenges and Opportunities in Engineering in vitro Muscle Satellite Cell Niches. *Differentiation* 2009, 78, 185–194. [PubMed: 19751902]
10. Fan Y; Maley M; Beilharz M; Grounds M, Rapid Death of Injected Myoblasts in Myoblast Transfer Therapy. *Muscle Nerve* 1996, 19, 853–860. [PubMed: 8965839]
11. Qu Z; Balkir L; van Deutekom JC; Robbins PD; Pruchnic R; Huard J, Development of Approaches to Improve Cell Survival in Myoblast Transfer Therapy. *J. Cell Biol* 1998, 142, 1257–1267. [PubMed: 9732286]
12. Qazi TH; Mooney DJ; Pumberger M; Geissler S; Duda GN, Biomaterials Based Strategies for Skeletal Muscle Tissue Engineering: Existing Technologies and Future Trends. *Biomaterials* 2015, 53, 502–521. [PubMed: 25890747]
13. Bach AD; Beier JP; Stern-Staeter J; Horch RE, Skeletal Muscle Tissue Engineering. *J. Cell Mol. Med* 2004, 8, 413–422. [PubMed: 15601570]
14. Gillies AR; Lieber RL, Structure and Function of the Skeletal Muscle Extracellular Matrix. *Muscle Nerve* 2011, 44, 318–331. [PubMed: 21949456]
15. Gillies AR; Chapman MA; Bushong EA; Deerinck TJ; Ellisman MH; Lieber RL, High Resolution Three-Dimensional Reconstruction of Fibrotic Skeletal Muscle Extracellular Matrix. *J. Physiol* 2017, 595, 1159–1171. [PubMed: 27859324]
16. Juhas M; Engelmayr GC, Jr.; Fontanella AN; Palmer GM; Bursac N, Biomimetic Engineered Muscle with Capacity for Vascular Integration and Functional Maturation in vivo. *Proc. Natl. Acad. Sci. U. S. A* 2014, 111, 5508–5513. [PubMed: 24706792]
17. Yang HS; Ieronimakis N; Tsui JH; Kim HN; Suh KY; Reyes M; Kim DH, Nanopatterned Muscle Cell Patches for Enhanced Myogenesis and Dystrophin Expression in a Mouse Model of Muscular Dystrophy. *Biomaterials* 2014, 35, 1478–1486. [PubMed: 24290810]
18. Choi JS; Lee SJ; Christ GJ; Atala A; Yoo JJ, The Influence of Electrospun Aligned Poly(epsilon-caprolactone)/Collagen Nanofiber Meshes on the Formation of Self-Aligned Skeletal Muscle Myotubes. *Biomaterials* 2008, 29, 2899–2906. [PubMed: 18400295]

19. Auger FA; Gibot L; Lacroix D, The Pivotal Role of Vascularization in Tissue Engineering. *Annu. Rev. Biomed. Eng* 2013, 15, 177–200. [PubMed: 23642245]
20. Levenberg S; Rouwkema J; Macdonald M; Garfein ES; Kohane DS; Darland DC; Marini R; van Blitterswijk CA; Mulligan RC; D'Amore PA; Langer R, Engineering Vascularized Skeletal Muscle Tissue. *Nat. Biotechnol* 2005, 23, 879–884. [PubMed: 15965465]
21. Richardson TP; Peters MC; Ennett AB; Mooney DJ, Polymeric System for Dual Growth Factor Delivery. *Nat. Biotechnol* 2001, 19, 1029–1034. [PubMed: 11689847]
22. Borselli C; Ungaro F; Oliviero O; d'Angelo I; Quaglia F; La Rotonda MI; Netti PA, Bioactivation of Collagen Matrices Through Sustained VEGF Release from PLGA Microspheres. *J. Biomed. Mater. Res. A* 2010, 92A, 94–102.
23. Demirdogen B; Elcin AE; Elcin YM, Neovascularization by bFGF Releasing Hyaluronic Acid-Gelatin Microspheres: in vitro and in vivo Studies. *Growth Factors* 2010, 28, 426–436. [PubMed: 20854186]
24. Karal-Yilmaz O; Serhatli M; Baysal K; Baysal BM, Preparation and in vitro Characterization of Vascular Endothelial Growth Factor (VEGF)-Loaded Poly(D,L-lactic-co-glycolic acid) Microspheres Using a Double Emulsion/Solvent Evaporation Technique. *J. Microencapsul* 2011, 28, 46–54. [PubMed: 21171816]
25. Chen RR; Silva EA; Yuen WW; Mooney DJ, Spatio-Temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation. *Pharm. Res* 2007, 24, 258–264. [PubMed: 17191092]
26. Olwin BB; Rapraeger A, Repression of Myogenic Differentiation by aFGF, bFGF, and K-FGF is Dependent on Cellular Heparan Sulfate. *J. Cell Biol* 1992, 118, 631–639. [PubMed: 1379245]
27. Pena TL; Chen SH; Konieczny SF; Rane SG, Ras/MEK/ERK Up-Regulation of the Fibroblast KCa Channel FIK is a Common Mechanism for Basic Fibroblast Growth Factor and Transforming Growth Factor-Beta Suppression of Myogenesis. *J. Biol. Chem* 2000, 275, 13677–13682. [PubMed: 10788486]
28. Lee OH; Kim YM; Lee YM; Moon EJ; Lee DJ; Kim JH; Kim KW; Kwon YG, Sphingosine 1-Phosphate Induces Angiogenesis: Its Angiogenic Action and Signaling Mechanism in Human Umbilical Vein Endothelial Cells. *Biochem. Biophys. Res. Commun* 1999, 264, 743–750. [PubMed: 10544002]
29. Liu Y; Wada R; Yamashita T; Mi Y; Deng CX; Hobson JP; Rosenfeldt HM; Nava VE; Chae SS; Lee MJ; Liu CH; Hla T; Spiegel S; Proia RL, Edg-1, the G Protein-Coupled Receptor for Sphingosine-1-Phosphate, is Essential for Vascular Maturation. *J. Clin. Invest* 2000, 106, 951–961. [PubMed: 11032855]
30. Nagata Y; Partridge TA; Matsuda R; Zammit PS, Entry of Muscle Satellite Cells into the Cell Cycle Requires Sphingolipid Signaling. *J. Cell Biol* 2006, 174, 245–253. [PubMed: 16847102]
31. Rapizzi E; Donati C; Cencetti F; Nincheri P; Bruni P, Sphingosine 1-Phosphate Differentially Regulates Proliferation of C2C12 Reserve Cells and Myoblasts. *Mol. Cell. Biochem* 2008, 314, 193–199. [PubMed: 18454302]
32. Lee H; Scherer NF; Messersmith PB, Single-Molecule Mechanics of Mussel Adhesion. *Proc. Natl. Acad. Sci. U. S. A* 2006, 103, 12999–3003. [PubMed: 16920796]
33. Suh KY; Park MC; Kim P, Capillary Force Lithography: A Versatile Tool for Structured Biomaterials Interface Towards Cell and Tissue Engineering. *Adv. Funct. Mater* 2009, 19, 2699–2712.
34. Kang SM; Hwang NS; Yeom J; Park SY; Messersmith PB; Choi IS; Langer R; Anderson DG; Lee H, One-Step Multipurpose Surface Functionalization by Adhesive Catecholamine. *Adv. Funct. Mater* 2012, 22, 2949–2955. [PubMed: 23580891]
35. Kailasa SK; Wu HF, One-Pot Synthesis of Dopamine Dithiocarbamate Functionalized Gold Nanoparticles for Quantitative Analysis of Small Molecules and Phosphopeptides in SALDI- and MALDI-MS. *Analyst* 2012, 137, 1629–1638. [PubMed: 22353931]
36. Nair PM; Salaita K; Petit RS; Groves JT, Using Patterned Supported Lipid Membranes to Investigate the Role of Receptor Organization in Intercellular Signaling. *Nat. Protoc* 2011, 6, 523–539. [PubMed: 21455188]

37. Song IT; Lee M; Lee H; Han J; Jang JH; Lee MS; Koh GY; Lee H, PEGylation and HAYlation via Catechol: α -Amine-Specific Reaction at N-terminus of Peptides and Proteins. *Acta Biomater* 2016, 43, 50–60. [PubMed: 27424082]
38. Rosen H; Stevens RC; Hanson M; Roberts E; Oldstone MB, Sphingosine-1-Phosphate and Its Receptors: Structure, Signaling, and Influence. *Annu. Rev. Biochem* 2013, 82, 637–662. [PubMed: 23527695]
39. O'Sullivan C; Dev KK, The Structure and Function of the S1P1 Receptor. *Trends Pharmacol. Sci* 2013, 34, 401–412. [PubMed: 23763867]
40. Seale P; Sabourin LA; Girgis-Gabardo A; Mansouri A; Gruss P; Rudnicki MA, Pax7 is Required for the Specification of Myogenic Satellite Cells. *Cell* 2000, 102, 777–786. [PubMed: 11030621]
41. von Maltzahn J; Jones AE; Parks RJ; Rudnicki MA, Pax7 is Critical for the Normal Function of Satellite Cells in Adult Skeletal Muscle. *Proc. Natl. Acad. Sci. U. S. A* 2013, 110, 16474–16479. [PubMed: 24065826]
42. Zammit PS; Relaix F; Nagata Y; Ruiz AP; Collins CA; Partridge TA; Beauchamp JR, Pax7 and Myogenic Progression in Skeletal Muscle Satellite Cells. *J. Cell Sci* 2006, 119, 1824–1832. [PubMed: 16608873]
43. Lepper C; Partridge TA; Fan CM, An Absolute Requirement for Pax7-Positive Satellite Cells in Acute Injury-Induced Skeletal Muscle Regeneration. *Development* 2011, 138, 3639–3646. [PubMed: 21828092]
44. Muzumdar MD; Tasic B; Miyamichi K; Li L; Luo L, A Global Double-Fluorescent Cre Reporter Mouse. *Genesis* 2007, 45, 593–605. [PubMed: 17868096]
45. Torgan CE; Daniels MP, Regulation of Myosin Heavy Chain Expression During Rat Skeletal Muscle Development in vitro. *Mol. Biol. Cell* 2001, 12, 1499–1508. [PubMed: 11359938]
46. Francetic T; Li Q, Skeletal Myogenesis and Myf5 Activation. *Transcription* 2011, 2, 109–114. [PubMed: 21922054]
47. Cooper RN; Tajbakhsh S; Mouly V; Cossu G; Buckingham M; Butler-Browne GS, *In vivo* Satellite Cell Activation via Myf5 and MyoD in Regenerating Mouse Skeletal Muscle. *J. Cell Sci* 1999, 112, 2895–2901. [PubMed: 10444384]
48. Gunther S; Kim J; Kostin S; Lepper C; Fan CM; Braun T, Myf5-Positive Satellite Cells Contribute to Pax7-Dependent Long-Term Maintenance of Adult Muscle Stem Cells. *Cell Stem Cell* 2013, 13, 590–601. [PubMed: 23933088]
49. Wagers AJ; Conboy IM, Cellular and Molecular Signatures of Muscle Regeneration: Current Concepts and Controversies in Adult Myogenesis. *Cell* 2005, 122, 659–667. [PubMed: 16143100]
50. Rossi AC; Mammucari C; Argentini C; Reggiani C; Schiaffino S, Two Novel/Ancient Myosins in Mammalian Skeletal Muscles: MYH14/7b and MYH15 Are Expressed in Extraocular Muscles and Muscle Spindles. *J. Physiol* 2010, 588, 353–364. [PubMed: 19948655]
51. Macadangang J; Guan X; Smith AS; Lucero R; Czerniecki S; Childers MK; Mack DL; Kim DH, Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. *Cell. Mol. Bioeng* 2015, 8, 320–332. [PubMed: 26366230]
52. Borges-Pereira L; Campos BR; Garcia CR, The GCaMP3 - A GFP-Based Calcium Sensor for Imaging Calcium Dynamics in the Human Malaria Parasite *Plasmodium falciparum*. *MethodsX* 2014, 1, 151–154. [PubMed: 26150947]
53. Zariwala HA; Borghuis BG; Hoogland TM; Madisen L; Tian L; De Zeeuw CI; Zeng H; Looger LL; Svoboda K; Chen TW, A Cre-Dependent GCaMP3 Reporter Mouse for Neuronal Imaging in vivo. *J. Neurosci* 2012, 32, 3131–3141. [PubMed: 22378886]
54. Kalka C; Masuda H; Takahashi T; Kalka-Moll WM; Silver M; Kearney M; Li T; Isner JM; Asahara T, Transplantation of ex vivo Expanded Endothelial Progenitor Cells for Therapeutic Neovascularization. *Proc. Natl. Acad. Sci. U. S. A* 2000, 97, 3422–3427. [PubMed: 10725398]
55. Danielli-Betto D; Peron S; Germinario E; Zanin M; Sorci G; Franzoso S; Sandona D; Betto R, Sphingosine 1-Phosphate Signaling is Involved in Skeletal Muscle Regeneration. *Am. J. Physiol., Cell Physiol* 2010, 298, C550–C558. [PubMed: 20042733]
56. Calise S; Blescia S; Cencetti F; Bernacchioni C; Donati C; Bruni P, Sphingosine 1-Phosphate Stimulates Proliferation and Migration of Satellite Cells: Role of S1P Receptors. *Biochim. Biophys. Acta* 2012, 1823, 439–450. [PubMed: 22178384]

57. Ieronimakis N; Pantoja M; Hays AL; Dosey TL; Qi J; Fischer KA; Hoofnagle AN; Sadilek M; Chamberlain JS; Ruohola-Baker H; Reyes M, Increased Sphingosine-1-Phosphate Improves Muscle Regeneration in Acutely Injured mdx Mice. *Skelet. Muscle* 2013, 3, 20. [PubMed: 23915702]
58. Allende ML; Yamashita T; Proia RL, G-Protein-Coupled Receptor S1P1 Acts Within Endothelial Cells to Regulate Vascular Maturation. *Blood* 2003, 102, 3665–3667. [PubMed: 12869509]
59. Blaho VA; Hla T, An Update on the Biology of Sphingosine 1-Phosphate Receptors. *J. Lipid Res* 2014, 55, 1596–1608. [PubMed: 24459205]
60. Spiegel S; Milstien S, Sphingosine-1-Phosphate: An Enigmatic Signalling Lipid. *Nat. Rev. Mol. Cell Biol* 2003, 4, 397–407. [PubMed: 12728273]
61. Hla T, Physiological and Pathological Actions of Sphingosine 1-Phosphate. *Semin. Cell Dev. Biol* 2004, 15, 513–520. [PubMed: 15271296]
62. Aarathi JJ; Darendeliler MA; Pushparaj PN, Dissecting the Role of the S1P/S1PR Axis in Health and Disease. *J. Dent. Res* 2011, 90, 841–854. [PubMed: 21248363]
63. Hannun YA; Obeid LM, Principles of Bioactive Lipid Signalling: Lessons from Sphingolipids. *Nat. Rev. Mol. Cell Biol* 2008, 9, 139–150. [PubMed: 18216770]
64. Loh KC; Leong WI; Carlson ME; Oskouian B; Kumar A; Fyrst H; Zhang M; Proia RL; Hoffman EP; Saba JD, Sphingosine-1-Phosphate Enhances Satellite Cell Activation in Dystrophic Muscles Through a S1PR2/STAT3 Signaling Pathway. *PLoS One* 2012, 7, e37218. [PubMed: 22606352]
65. Sassoli C; Formigli L; Bini F; Tani A; Squecco R; Battistini C; Zecchi-Orlandini S; Francini F; Meacci E, Effects of S1P on Skeletal Muscle Repair/Regeneration During Eccentric Contraction. *J. Cell. Mol. Med* 2011, 15, 2498–2511. [PubMed: 21199328]
66. Meacci E; Cencetti F; Formigli L; Squecco R; Donati C; Tiribilli B; Quercioli F; Zecchi Orlandini S; Francini F; Bruni P, Sphingosine 1-Phosphate Evokes Calcium Signals in C2C12 Myoblasts via Edg3 and Edg5 Receptors. *Biochem. J* 2002, 362, 349–357. [PubMed: 11853542]
67. Porter GA, Jr.; Makuck RF; Rivkees SA, Reduction in Intracellular Calcium Levels Inhibits Myoblast Differentiation. *J. Biol. Chem* 2002, 277, 28942–28947. [PubMed: 12042317]
68. Travaglione S; Messina G; Fabbri A; Falzano L; Giammarioli AM; Grossi M; Rufini S; Fiorentini C, Cytotoxic Necrotizing Factor 1 Hinders Skeletal Muscle Differentiation in vitro by Perturbing the Activation/Deactivation Balance of Rho GTPases. *Cell Death Differ* 2005, 12, 78–86. [PubMed: 15514676]
69. Formigli L; Meacci E; Sassoli C; Chellini F; Giannini R; Quercioli F; Tiribilli B; Squecco R; Bruni P; Francini F; Zecchi-Orlandini S, Sphingosine 1-Phosphate Induces Cytoskeletal Reorganization in C2C12 Myoblasts: Physiological Relevance for Stress Fibres in the Modulation of Ion Current Through Stretch-Activated Channels. *J. Cell Sci* 2005, 118, 1161–1171. [PubMed: 15728255]
70. Benavides Damm T; Egli M, Calcium's Role in Mechanotransduction During Muscle Development. *Cell. Physiol. Biochem* 2014, 33, 249–272. [PubMed: 24525559]
71. Lai KM; Gonzalez M; Poueymirou WT; Kline WO; Na E; Zlotchenko E; Stitt TN; Economides AN; Yancopoulos GD; Glass DJ, Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy. *Mol. Cell. Biol* 2004, 24, 9295–9304. [PubMed: 15485899]
72. Briata P; Lin WJ; Giovarelli M; Pasero M; Chou CF; Trabucchi M; Rosenfeld MG; Chen CY; Gherzi R, PI3K/AKT Signaling Determines a Dynamic Switch Between Distinct KSRP Functions Favoring Skeletal Myogenesis. *Cell Death Differ* 2012, 19, 478–487. [PubMed: 21886180]
73. Garcia JG; Liu F; Verin AD; Birukova A; Dechert MA; Gerthoffer WT; Bamberg JR; English D, Sphingosine 1-Phosphate Promotes Endothelial Cell Barrier Integrity by Edg-Dependent Cytoskeletal Rearrangement. *J. Clin. Invest* 2001, 108, 689–701. [PubMed: 11544274]
74. Lee MJ; Thangada S; Claffey KP; Ancellin N; Liu CH; Kluk M; Volpi M; Sha'afi RI; Hla T, Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate. *Cell* 1999, 99, 301–312. [PubMed: 10555146]
75. Igarashi J; Michel T, S1P and eNOS Regulation. *Biochim. Biophys. Acta* 2008, 1781, 489–495. [PubMed: 18638569]
76. Jung B; Obinata H; Galvani S; Mendelson K; Ding BS; Skoura A; Kinzel B; Brinkmann V; Rafii S; Evans T; Hla T, Flow-Regulated Endothelial S1P Receptor-1 Signaling Sustains Vascular Development. *Dev. Cell* 2012, 23, 600–610. [PubMed: 22975328]

77. Gaengel K; Niaudet C; Hagikura K; Lavina B; Muhl L; Hofmann JJ; Ebarasi L; Nystrom S; Rymo S; Chen LL; Pang MF; Jin Y; Raschperger E; Roswall P; Schulte D; Benedito R; Larsson J; Hellstrom M; Fuxe J; Uhlen P; Adams R; Jakobsson L; Majumdar A; Vestweber D; Uv A; Betsholtz C, The Sphingosine-1-Phosphate Receptor S1PR1 Restricts Sprouting Angiogenesis by Regulating the Interplay Between VE-Cadherin and VEGFR2. *Dev. Cell* 2012, 23, 587–599. [PubMed: 22975327]
78. Liu F; Verin AD; Wang P; Day R; Wersto RP; Chrest FJ; English DK; Garcia JG, Differential Regulation of Sphingosine-1-Phosphate-and VEGF-Induced Endothelial Cell Chemotaxis. Involvement of Gi α 2-Linked Rho Kinase Activity. *Am. J. Respir. Cell Mol. Biol* 2001, 24, 711–719. [PubMed: 11415936]
79. Bryan BA; Walshe TE; Mitchell DC; Havumaki JS; Saint-Geniez M; Maharaj AS; Maldonado AE; D'Amore PA, Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic Differentiation. *Mol. Biol. Cell* 2008, 19, 994–1006. [PubMed: 18094043]
80. Christov C; Chretien F; Abou-Khalil R; Bassez G; Vallet G; Authier FJ; Bassaglia Y; Shinin V; Tajbakhsh S; Chazaud B; Gherardi RK, Muscle Satellite Cells and Endothelial Cells: Close Neighbors and Privileged Partners. *Mol. Biol. Cell* 2007, 18, 1397–1409. [PubMed: 17287398]
81. Hannun YA; Obeid LM, The Ceramide-Centric Universe of Lipid-Mediated Cell Regulation: Stress Encounters of the Lipid Kind. *J. Biol. Chem* 2002, 277, 25847–25850. [PubMed: 12011103]
82. Kolesnick R, The Therapeutic Potential of Modulating the Ceramide/Sphingomyelin Pathway. *J. Clin. Invest* 2002, 110, 3–8. [PubMed: 12093880]
83. Hait NC; Oskeritzian CA; Paugh SW; Milstien S; Spiegel S, Sphingosine Kinases, Sphingosine 1-Phosphate, Apoptosis and Diseases. *Biochim. Biophys. Acta* 2006, 1758, 2016–2026. [PubMed: 16996023]
84. Cuvillier O; Pirianov G; Kleuser B; Vanek PG; Coso OA; Gutkind S; Spiegel S, Suppression of Ceramide-Mediated Programmed Cell Death by Sphingosine-1-Phosphate. *Nature* 1996, 381, 800–803. [PubMed: 8657285]
85. Laviad EL; Albee L; Pankova-Kholmyansky I; Epstein S; Park H; Merrill AH, Jr.; Futerman AH, Characterization of Ceramide Synthase 2: Tissue Distribution, Substrate Specificity, and Inhibition by Sphingosine 1-Phosphate. *J. Biol. Chem* 2008, 283, 5677–5684. [PubMed: 18165233]
86. Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JGN; Natarajan V, FTY720 Inhibits Ceramide Synthases and Up-regulates Dihydrosphingosine 1-Phosphate Formation in Human Lung Endothelial Cells. *J. Biol. Chem* 2009, 284, 5467–5477. [PubMed: 19119142]
87. Carson D; Hnilova M; Yang X; Nemeth CL; Tsui JH; Smith AS; Jiao A; Regnier M; Murry CE; Tamerler C; Kim DH, Nanotopography-Induced Structural Anisotropy and Sarcomere Development in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells. *ACS Appl. Mater. Interfaces* 2016, 8, 21923–21932. [PubMed: 26866596]
88. Jiao A; Trosper NE; Yang HS; Kim J; Tsui JH; Frankel SD; Murry CE; Kim DH, Thermoresponsive Nanofabricated Substratum for the Engineering of Three-Dimensional Tissues with Layer-by-Layer Architectural Control. *ACS Nano* 2014, 8, 4430–4439. [PubMed: 24628277]
89. Lepper C; Conway SJ; Fan CM, Adult Satellite Cells and Embryonic Muscle Progenitors Have Distinct Genetic Requirements. *Nature* 2009, 460, 627–631. [PubMed: 19554048]
90. Ieronimakis N; Balasundaram G; Rainey S; Srirangam K; Yablonka-Reuveni Z; Reyes M, Absence of CD34 on Murine Skeletal Muscle Satellite Cells Marks a Reversible State of Activation During Acute Injury. *PLoS One* 2010, 5, e10920. [PubMed: 20532193]
91. Ieronimakis N; Balasundaram G; Reyes M, Direct Isolation, Culture and Transplant of Mouse Skeletal Muscle Derived Endothelial Cells with Angiogenic Potential. *PLoS One* 2008, 3, e0001753. [PubMed: 18335025]
92. Pratumvinit B; Reesukumal K; Janebodin K; Ieronimakis N; Reyes M, Isolation, Characterization, and Transplantation of Cardiac Endothelial Cells. *BioMed Res. Int* 2013, 2013, 359412. [PubMed: 24282814]
93. Lo CG; Xu Y; Proia RL; Cyster JG, Cyclical Modulation of Sphingosine-1-Phosphate Receptor 1 Surface Expression During Lymphocyte Recirculation and Relationship to Lymphoid Organ Transit. *J. Exp. Med* 2005, 201, 291–301. [PubMed: 15657295]

Figure 1. Fabrication and functionalization of biodegradable S1P-conjugated nanopatterned substrates.

(a) PLGA is nanopatterned using capillary force lithography and functionalized with S1P with one-pot DOPA-mediated chemistry. (b) XPS analysis confirms S1P conjugation to substrate surfaces. Spectra shown is a survey scan in which nitrogen (N1s) and phosphorous (P2p) peaks characteristic of S1P appear post-functionalization (red spectra).

Figure 2. S1P signaling and nanotopographical cues induce greater myogenic potential of cultured primary satellite cells and myoblasts.

(a) Representative fluorescent images of cells and myotubes that are Pax7⁺ (green), which identifies them as either progeny of differentiated myogenic progenitor cells, or are progenitors themselves. Scale bars: 50 μ m; direction of nanopatterning indicated by white double arrows. (b) Quantitative analyses of Pax7-GFP imaging for indicators of active myogenesis and myotube development. All quantitative data are presented as means $\pm$ SEM, n = 10 different cultures. *p < 0.05, **p < 0.01, ***p < 0.001 (comparing groups within substrate topography; one-way ANOVA with Tukey's *post-hoc*); #p < 0.05 (comparing flat vs. patterned at the same S1P concentration; Student's *t*-test).

Figure 3. S1P signaling and nanotopographical cues enhance the maturation of differentiated muscle cells.

(a) Representative images of myotubes stained for MHC (pseudo-color in green). Scale bars: 50 μm; direction of nanopatterning indicated by white double arrows. (b) Images were analyzed for the total number of MHC⁺ myotubes, with the greatest number seen on nanopatterned substrates functionalized with 175 μM S1P. (c) qRT-PCR analyses of primary muscle cells cultured on substrates for 10 days. Genes examined are markers representative of progenitor activation (*Pax7*) and various stages of myogenic differentiation, ranging from immature (*Myf5*) to more mature (*MyoD*, *MyoG*, *Myh15*). All quantitative data are presented as means ± SEM, n = 10 different cultures. *p < 0.05, **p < 0.01, ***p < 0.001 (comparing groups within substrate topography; one-way ANOVA with Tukey's *post-hoc*); #p < 0.05 (comparing flat vs. patterned at the same S1P concentration; Student's *t*-test).

Figure 4. Enhanced myogenic maturation leads to improved skeletal muscle tissue function.

(a) The average contraction displacement of myotubes on flat or patterned substrates with and without 175 μM S1P. The combination of patterning and S1P led to the largest displacements. (b) The average contraction velocity of myotubes on flat or patterned substrates with and without 175 μM S1P. Myotubes developed from cells on patterned substrates functionalized with S1P contracted with the greatest velocities. (c) Representative traces of fluorescence intensity over time for myotubes on flat (blue) and nanopatterned substrates with 175 μM S1P (red) illustrating their respective contractile regularity. (d) Average fluorescence intensities of contracting GCaMP-expressing myotubes on flat or patterned substrates with and without 175 μM S1P. All quantitative data are presented as means $\pm$ SEM, $n = 10$ different cultures. * $p < 0.05$, ** $p < 0.01$ (comparing groups within substrate topography; Student's t -test); # $p < 0.05$ (comparing flat vs. patterned at the same S1P concentration; Student's t -test).

Figure 5. S1P induces endothelial cell differentiation and enhanced pre-vascularization in a dose-dependent manner.

(a) Staining for BS1 (pseudo-green), an endothelial cell marker, shows significantly greater numbers of BS1⁺ cells on substrates with S1P, regardless of underlying nanotopography. Interestingly, some endothelial cells appear to localize around formed myotubes (pseudo-red). Scale bars: 50 μm; direction of nanopatterning indicated by white double arrows. (b) Quantification of BS1 staining, with the greatest number of positively-stained cells present on 250 μM S1P-functionalized substrates. (c) qRT-PCR assays show an increased expression of endothelial cell (CD31) and vascular development markers (*vWF*, *eNOS*, *Ve-Cad*) with respect to increasing S1P concentration. All quantitative data are presented as means ± SEM, n = 10 different cultures. *p < 0.05, **p < 0.01, ***p < 0.001 (comparing groups within substrate topography; one-way ANOVA with Tukey's *post-hoc*); #p < 0.05 (comparing flat vs. patterned at the same S1P concentration; Student's *t*-test).

Figure 6. Flox-out of S1P₁ results in predominantly nanotopography-mediated myogenic differentiation and maturation.

(a) There is no significant difference in the number of MHC⁺ myotubes when comparing functionalization states in S1P₁ flox-out cultures. However, myotube formation and alignment is still enhanced by nanotopography. Scale bars: 100 μm ; direction of nanotopography indicated by white double arrows. (b) Quantification of MHC staining further illustrates the lack of S1P-induced myogenic maturation. (c) qRT-PCR of representative genetic markers for myogenesis, where marker expression is increased in the presence of biomimetic nanotopography, but not in the presence of S1P. (d) Gene marker analysis of markers for endothelial cells and vascular integrity illustrate continued effect of S1P on non-myogenic cells. All quantitative data are presented as means $\pm$ SEM, $n = 10$ different cultures. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (comparing groups within substrate).

topography; Student's *t*-test); # $p < 0.05$ (comparing flat vs. patterned at the same S1P concentration; Student's *t*-test).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 7. Inhibition of VEGFR2 in cells cultured on substrates functionalized with 175 μ M S1P results in reduced skeletal muscle and endothelial maturation.

(a) Expression of markers for late-stage or terminal differentiation were significantly downregulated in comparison to cells in which VEGFR2 function was uninhibited. (b) Expression markers for vascular endothelial maturation were significantly downregulated in the presence of cabozantinib. All quantitative data are presented as means $\pm$ SEM, $n=6$ different cultures. * $p < 0.05$, ** $p < 0.01$ (Student's t -test).